Full history for every metric is available with a Kvantra account
Misonix, Inc. (MSON)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 23 | 27 | 37 | 39 | 62 | 74 | 74 |
| Operating profit | $m | -11 | -11 | |||||
| Net profit | $m | -1 | -2 | -8 | -7 | -17 | -14 | -14 |
| EPS reported | $ | -0.99 | -0.84 | |||||
| Operating cashflow per share | $ | -0.61 | -0.61 | |||||
| Capex per share | $ | 0.02 | 0.02 | |||||
| FCF per share | $ | -0.63 | -0.63 | |||||
| Free cash flow | $m | -9 | -9 | |||||
| Net debt | $m | 16 | 15 | |||||
| Book value equity | $m | 135 | 135 | |||||
| Book value per share | $ | 9.22 | 7.85 | |||||
| Number of shares | m | 14.67 | 17.23 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.41 | 3.38 | |||||
| P/S LTM | x | 4.40 | 6.18 | |||||
| P/FCF LTM | x | -35.06 | -49.40 | |||||
| EV/EBITDA LTM | x | -55.53 | -76.75 | |||||
| EV/Sales LTM | x | 4.61 | 6.38 | |||||
| Earnings Yield LTM | % | -4.45% | -3.72% | |||||
| FCF Yield | % | -2.85% | -2.02% | |||||
| Quality | ||||||||
| ROE | % | -10.71% | -10.27% | |||||
| ROIC | % | -6.02% | -6.02% | |||||
| Operating margin | % | -14.91% | -14.91% | |||||
| Gross margin | % | 71.11% | 71.11% | |||||
| FCF/Sales | % | -12.54% | -12.54% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +18.47% | +18.47% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.20 | -0.20 | |||||
| Net Debt/EBITDA | x | -2.62 | -2.62 | |||||
| EBIT/Net interest | x | -3.05 | -3.05 | |||||
| Net debt/market cap | % | 4.94% | 3.23% | |||||
| Net debt/Equity | x | 0.12 | 0.11 | |||||
| Gross debt/equity | x | 0.35 | 0.35 | |||||
Company overview
Misonix, Inc., operating alongside its subsidiary entities, specializes in the development, manufacturing, and global commercialization of minimally invasive ultrasonic surgical medical devices. These products serve markets within the United States and internationally. Among its offerings is the BoneScalpel, an ultrasonic system enabling precise cutting and shaping of bone during surgical interventions while carefully preserving surrounding soft tissue. Another key innovation is SonaStar, a surgical aspirator designed to emulsify and extract both soft and hard tumors, predominantly utilized in neurological and general surgical settings. The company also provides SonicOne, an ultrasonic cleansing and debridement solution that specifically targets and removes devitalized tissue and fibrin deposits from wounds and burns, ensuring the protection of viable cells. These instruments find application across a range of clinical disciplines, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound management, and maxillofacial procedures. Sales of its products are conducted through a network of sales representatives and authorized distributors. Misonix, Inc. was established in 1959 and maintains its corporate headquarters in Farmingdale, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Misonix, Inc. (MSON)
Misonix, Inc., operating alongside its subsidiary entities, specializes in the development, manufacturing, and global commercialization of minimally invasive ultrasonic surgical medical devices. These products serve markets within the United States and internationally. Among its offerings is the BoneScalpel, an ultrasonic system enabling precise cutting and shaping of bone during surgical interventions while carefully preserving surrounding soft tissue. Another key innovation is SonaStar, a surgical aspirator designed to emulsify and extract both soft and hard tumors, predominantly utilized in neurological and general surgical settings. The company also provides SonicOne, an ultrasonic cleansing and debridement solution that specifically targets and removes devitalized tissue and fibrin deposits from wounds and burns, ensuring the protection of viable cells. These instruments find application across a range of clinical disciplines, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound management, and maxillofacial procedures. Sales of its products are conducted through a network of sales representatives and authorized distributors. Misonix, Inc. was established in 1959 and maintains its corporate headquarters in Farmingdale, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free